DK1163008T3 - Use of trehalose to stabilize a liquid vaccine - Google Patents

Use of trehalose to stabilize a liquid vaccine

Info

Publication number
DK1163008T3
DK1163008T3 DK00912734T DK00912734T DK1163008T3 DK 1163008 T3 DK1163008 T3 DK 1163008T3 DK 00912734 T DK00912734 T DK 00912734T DK 00912734 T DK00912734 T DK 00912734T DK 1163008 T3 DK1163008 T3 DK 1163008T3
Authority
DK
Denmark
Prior art keywords
trehalose
liquid vaccine
stabilize
vaccine composition
liquid
Prior art date
Application number
DK00912734T
Other languages
Danish (da)
Inventor
Graf Sandrine Lentsch
Jean-Rene Cartier
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of DK1163008T3 publication Critical patent/DK1163008T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Abstract

The invention concerns a liquid vaccine composition comprising at least an antigen consisting of a polysaccharide bound to a carrier protein and trehalose. The invention also concerns a method for stabilising a liquid vaccine composition which consists in adding trehalose to the vaccine composition.
DK00912734T 1999-03-23 2000-03-23 Use of trehalose to stabilize a liquid vaccine DK1163008T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903765A FR2791895B1 (en) 1999-03-23 1999-03-23 USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
PCT/FR2000/000730 WO2000056365A1 (en) 1999-03-23 2000-03-23 Use of trehalose for stabilising a liquid vaccine

Publications (1)

Publication Number Publication Date
DK1163008T3 true DK1163008T3 (en) 2003-11-17

Family

ID=9543654

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00912734T DK1163008T3 (en) 1999-03-23 2000-03-23 Use of trehalose to stabilize a liquid vaccine

Country Status (11)

Country Link
EP (1) EP1163008B1 (en)
JP (1) JP2002540079A (en)
AT (1) ATE246937T1 (en)
AU (1) AU3438900A (en)
CA (1) CA2366869A1 (en)
DE (1) DE60004496T2 (en)
DK (1) DK1163008T3 (en)
ES (1) ES2200845T3 (en)
FR (1) FR2791895B1 (en)
PT (1) PT1163008E (en)
WO (1) WO2000056365A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737413T2 (en) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville BACTERIOFERRITINE FROM HELICOBACTER PYLORI
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
JP4697706B2 (en) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Polypeptide-vaccine for broad protection against highly virulent meningococcal strains
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP4738339B2 (en) 2003-10-02 2011-08-03 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Liquid vaccine for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
MX2008014391A (en) * 2006-05-12 2009-03-06 Bharat Biotech Int Ltd A composition useful as a vaccine.
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
BRPI0810778A2 (en) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, combined vaccine, and methods of decreasing crm neighborhood interference over a sensitive antigen in a primary immunization schedule of a vaccine, and decreasing neighborhood interference over a sensitive antigen, and use of saccharide conjugates
HUE037932T2 (en) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Pharmaceutical compositions containing clostridium difficile toxoids a and b
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
EP2544713A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Immunogenic composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
GB201016969D0 (en) 2010-10-08 2010-11-24 Genome Res Ltd Expression system
CN102793919A (en) 2011-05-20 2012-11-28 日东电工株式会社 Pharmaceutical composition and method for producing the same
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
WO2013083753A2 (en) 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
ES2820898T3 (en) 2012-05-22 2021-04-22 Glaxosmithkline Biologicals Sa Meningococcal serogroup X conjugate
FR2992656B1 (en) * 2012-07-02 2016-10-07 Sanofi Pasteur METHOD FOR PRODUCING ANTIGENS HAEMOPHILUS INFLUENZAE TYPE B
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
WO2014053612A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic composition
JP6431484B2 (en) * 2012-12-28 2018-11-28 セルスティス リミテッド Cell-mediated immune response assay
WO2017175082A1 (en) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Immunogenic compositions
CN109890413B (en) 2016-09-02 2024-04-16 赛诺菲巴斯德股份有限公司 Neisseria meningitidis vaccine
US11149255B2 (en) 2016-09-06 2021-10-19 Bioventures, Llc Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
MX2019010461A (en) 2017-03-03 2020-01-09 Treos Bio Zrt Personalised immunogenic peptide identification platform.
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
KR20210086612A (en) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 peptide vaccine
MX2021005303A (en) 2018-11-06 2021-07-07 Glaxosmithkline Biologicals Sa Immunogenic compositions.
GB201908332D0 (en) 2019-06-11 2019-07-24 Univ Oxford Innovation Ltd Assays and inhibitors of oxygen-dependent N-terminal oxidation
WO2021198705A1 (en) 2020-04-03 2021-10-07 Peptc Vaccines Limited Coronavirus vaccine
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
GB202109082D0 (en) 2021-06-24 2021-08-11 Univ Oxford Innovation Ltd Polypeptides and uses thereof
WO2023148333A1 (en) 2022-02-03 2023-08-10 CeCaVa GmbH & Co. KG Co-vaccination with cd4 and cd8 antigens
GB202208695D0 (en) 2022-06-14 2022-07-27 Univ Oxford Innovation Ltd Antibacterials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748132A1 (en) * 1977-10-27 1979-05-03 Behringwerke Ag STABILIZER FOR POLYSACCHARIDE
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
ES2137310T3 (en) * 1993-05-17 1999-12-16 Akzo Nobel Nv VACCINE AGAINST STREPTOCOCCUS SUIS INFECTION.
DE69530196T2 (en) * 1994-06-02 2003-11-20 Elan Drug Delivery Ltd METHOD FOR PREVENTING THE AGGREGATION OF PROTEINS / PEPTIDES IN REHYDRATION OR THAWING
ES2294801T3 (en) * 1996-09-26 2008-04-01 MERCK & CO., INC. FORMULATIONS OF VACCINES AGAINST ROTAVIRUS.
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
EP1163008B1 (en) 2003-08-13
PT1163008E (en) 2003-12-31
FR2791895A1 (en) 2000-10-13
AU3438900A (en) 2000-10-09
WO2000056365A1 (en) 2000-09-28
DE60004496T2 (en) 2004-04-08
CA2366869A1 (en) 2000-09-28
ATE246937T1 (en) 2003-08-15
EP1163008A1 (en) 2001-12-19
ES2200845T3 (en) 2004-03-16
FR2791895B1 (en) 2001-06-15
DE60004496D1 (en) 2003-09-18
JP2002540079A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
DK1163008T3 (en) Use of trehalose to stabilize a liquid vaccine
CY2019029I1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
BR0114646A (en) humanized anti-lt-beta-r antibodies
UA93855C2 (en) Neutralizing epitope-based growth enhancing vaccine
CY1112687T1 (en) METHOD FOR USING DICTIONARIES AND COMPOSITIONS THAT INCLUDE
YU9404A (en) Peptide-based multimeric targeted contrast agents
DK1098649T3 (en) Method for Stabilizing Pharmaceutical Compositions with Special Use of Antioxidant
ATE289640T1 (en) AMIDOFUNCTIONAL AMINOPOLYDIORGANOSILOXANES
DE60144145D1 (en) Subtilisin variant
EA200200105A1 (en) Compounds modulating PPARγ activity;
DE69431358D1 (en) METHOD AND COMPOSITIONS FOR MICRO-ENCLOSURE ADJUVANTS
DE60007095D1 (en) CALANOLIDE FOR INHIBITING BTK
DE60125797D1 (en) IMPFSTOFFZUSAMMESETZUNG
FI20012281A0 (en) Method and system for generating personalized messages
WO2003104425A3 (en) Novel stable anti-cd22 antibodies
ATE551069T1 (en) MUCIN FUSION POLYPEPTIDE VACCINES, COMPOSITIONS AND USE THEREOF
ATE297761T1 (en) PREPARATIONS FOR STABILIZING PEG-INTERFERON ALPHA CONJUGATES
DK1235579T3 (en) Pharmaceuticals containing trimegestone
ATE352315T1 (en) NEOSPORA VACCINE
DE60222296D1 (en) VACCINATED VIRUS AND METHOD FOR THE PRODUCTION THEREOF
DE69840637D1 (en) COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINES USING CHEMOKINS
DE10292736D2 (en) Flooring
BR0110205A (en) Peptide deformylase inhibitors
DE60024977D1 (en) CLONING AND EXPRESSION OF HAEMOPHILUS SOMNUS TRANSFERRIN-BINDING PROTEINS
IT1308583B1 (en) CONSOLIDATION PROCEDURE FOR LAND AND BUILDINGS.